Therapy results of 91 patients with newly diagnosed multiple myeloma who received autologous hematopoietic stem cells transplantation are presented. According to our data, survival depends on the preransplant response and the amount of transplantations. 5-years progressionfree survival in patients, achieved pre-transplant complete or almost complete remission and received one auto-HSCT was 40 % compared with 18 % in patients who achieved only a partial response (p = 0.07). 10-years overall survival in patients received tandem auto-HSCT was
40 % compared with 20 % in patients after one auto-HSCT. Statistically significant differences in 5-years progression-free survival (34 % after tandem auto-HSCT vs. 22 % after one auto-HSCT; p = 0.004) also were revealed.

Hodgkin’s lymphoma (HL) is highly sensitive to chemo- and radiotherapy. Long-term tumor-free survival in patients with early stages is close to 95–98 %. Therapy results in patients with advanced stages is worse that requires an intensification of treatment and creates the issues
of late toxicity prevention. These problems are especially relevant in young adults with a life expectancy of 40 years or more. Escalated BEACOPP protocol developed by the German study group allows to achieve cure the majority of patients with advanced-stage Hodgkin’s lymphoma, but this regime has significant toxicity. It causes infertility in almost all patients. BEACOPP-14 with comparable activity contains less cumulative doses of potentially gonadotoxic alkylating agents. Efficacy and toxicity of this regime has been analyzed in 29 patients with prognostically unfavorable stages of HL (m – 13, f – 16) received 8 courses BEACOPP-14 without a dose reduction of cytostatics. The median age of patients was 24 (20–35) years. With a median follow-up of 32.8 (4–66) months, event-free survival was 92.8 %, disease-free – 96.2 %, and overall survival – 95.2 %. Of the 16 women included in the study, the menstrual cycle was restored in 14 patients during 3–6 months. 2 patients were not evaluated because of switch to more intensive chemotherapy in the early stages of treatment. Of the remaining 14 patients pregnancy occurred in 3 (18.7 %), delivery – in 2, abortion – in 1. Delivery was term, children born healthy. Most of the patients according to the doctors’ recommendations protects and continues to avoid pregnancy for 2 years after treatment. The data indicate a potentially less reproductive damaging of BEACOPP-14 in females retaining high anti-tumor efficacy.

Currently high-doses chemotherapy (HD-PCT) + autologous hematopoietic stem cells transplantation (auto-HSCT) is the treatment of
choice in patients with recurrent and progressive lymphomas. Most of quality of life (QoL) studies in lymphomas patients received HSCT limited on parameters dynamics assessment in the early and late post-transplant period. Aim of this study was to evaluate the QoL parameters and their prognostic significance in lymphoma patients before transplantation. 124 patients with lymphomas (non-Hodgkin lymphomas – 45 patients, Hodgkin's lymphoma – 79 patients) who received HD-PCT + auto-HSCT were included in the study: men – 42.7 % (n = 53), women – 57.3 % (n = 71), median age – 34 years (19–65 years). Patients’ heterogeneity before transplantation regarding quality of life has been revealed. Almost 1/3 of patients showed a significant reduction in the integral index of QoL. Insignificant differences between patients with chemosensitivity and chemoresistant lymphomas regarding QoL before HD-PCT + auto-HSCT were shown. We also analyzed the outcomes of studied patients received HD-PCT + auto-HSCT. With a median follow-up of 18 months, overall survival after transplantation was 72 % (95 % CI 56–84); event-free survival – 64 % (95 % CI 53,3–73,2).
Overall and event-free survivals were significantly higher in patients with chemosensitive lymphoma compared with chemoresistance tumor. Differences in the survival rates between patients with no or negligible decrease of QoL integral index and with significant reduction of it also were found. Revealed differences in overall and event-free survival between the groups allowed the first group considered as patients with a favorable prognosis, and the second group – as patients with poor prognosis regarding the transplantation outcome.

Resting energy expenditure (REE) by indirect calorimetry and body composition by bioimpedance analysis are studied in three groups of children aged 5–18 years. Group 1 (n = 181) – patients in remission of cancer, group 2 (n = 55) – children with oncology diseases receiving chemotherapy or who are in the early period after hematopoietic stem cell transplantation, group 3 (n = 63) – children with non-malignant diseases of the gastrointestinal tract. To eliminate the influence of age and gender on the intergroup comparisons, body composition parameters were expressed as standardized values (z-scores) relative to a reference group of healthy Russian children (n = 138,191). Group 1 was characterized by excess fat content with intact lean body mass, and groups 2 and 3 by protein depletion, more pronounced in Group 2 with a higher percentage of body fat. All used conventional formulas (WHO, Harris–Benedict and others) in groups 1 and 3 underestimated REE as compared with indirect calorimetry. A new formula for REE, giving an unbiased estimate in the group 1 was proposed: REE (kcal/day) = 28.7 × BCM (kg) +10.5 × Height (cm) – 38.6 × Age (years) – 134, where BCM – body cell mass according to bioimpedance analysis (R2 = 0.67, the standard deviation of 196 kcal/day).

An overview of the literature data concerning the comparison of toxicity, efficacy and cost of amphotericin B lipid complex and liposomal amphotericin B, as well as their comparison with amphotericin B deoxycholate are provided.

Twenty patients with primary immune thrombocytopenia (ITP) received romiplastim as a second line therapy, and 3 patients with secondary thrombocytopenia as off-label. Romiplostim appeared effective in 85 % of patients with both persistent and chronic primary ITP. In patients with resistant and refractory ITP romiplostim response has not been registered, or it was lost. Achieving complete response to romiplostim therapy allowed its cancelation in 30 % of patients while maintaining the therapeutic effect; 15 % of patients switched to the 1 injection/biweekly in doses 4–5 mg/kg. Adverse events were observed in 21 % of patients and were temporary. With long-term use drug efficacy is not reduced, and the frequency of adverse events do not increase. Short course of romiplostim was successfully applied before surgical intervention for correction of thrombocytopenia in 3 patients with rheumatic diseases.

Obligatory detection of vWF blood levels, progesterone and testosterone levels in addition to routine tests are necessary to identify the causes of juvenile uterine bleeding. If progesterone level less than 1.75 ng/ml, and vWF activity in first phase of the cycle varies in the range 30–39 %, hyperpolymenorrhea may be due to coagulation disorders. Diagnostic range of vWF activity, within which hyperpolymenorrhea considered as a clinical sign of latent coagulation “disorders”, should be extended to 35 % for patients with O(I) blood group and to 39 % for patients with A (II), B (III) and AB (IV) blood group.